Literature DB >> 30877210

Factors Associated with Relapse and Dependence on Glucocorticoids in Giant Cell Arteritis.

Anael Dumont1,2, Jean-Jacques Parienti1,2, Claire Delmas1,2, Jonathan Boutemy1,2, Gwénola Maigné1,2, Nicolas Martin Silva1,2, Audrey Sultan1,2, Gaétane Planchard1,2, Achille Aouba1,2, Hubert de Boysson3,4.   

Abstract

OBJECTIVE: To identify characteristics and factors associated with relapse and glucocorticoid (GC) dependence in patients with giant cell arteritis (GCA).
METHODS: We retrospectively analyzed 326 consecutive patients with GCA followed for at least 12 months. Factors associated with relapse and GC dependence were identified in multivariable analyses.
RESULTS: The 326 patients (73% women) were followed up for 62 (12-262) months. During followup, 171 (52%) patients relapsed, including 113 (35%) who developed GC dependence. Relapsing patients had less history of stroke (p = 0.01) and presented large-vessel vasculitis (LVV) more frequently on imaging (p = 0.01) than patients without relapse. During the first months, therapeutic strategy did not differ among relapsing and nonrelapsing patients. GC-dependent patients were less likely to have a history of stroke (p = 0.004) and presented LVV on imaging more frequently (p = 0.005) than patients without GC-dependent disease. In multivariable analyses, LVV was an independent predictive factor of relapse (HR 1.49, 95% CI 1.002-2.12; p = 0.04) and GC dependence (OR 2.19, 95% CI 1.19-4.05; p = 0.01). Conversely, stroke was a protective factor against relapse (HR 0.21, 95% CI 0.03-0.68; p = 0.005) and GC-dependent disease (OR 0.10, 95% CI 0.001-0.31; p = 0.0005). Patients with a GC-dependent disease who received a GC-sparing agent had a shorter GC treatment duration than those without (p = 0.008).
CONCLUSION: In this study, LVV was an independent predictor of relapse and GC dependence. Further prospective studies are needed to confirm these findings and to determine whether patients with LVV require a different treatment approach.

Entities:  

Keywords:  GIANT CELL ARTERITIS; GLUCOCORTICOID DEPENDENCE; GLUCOCORTICOIDS; LARGE-VESSEL VASCULITIS; RELAPSE

Mesh:

Substances:

Year:  2019        PMID: 30877210     DOI: 10.3899/jrheum.181127

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

Review 1.  [Glucocorticoids in the treatment of giant cell arteritis : How much, how long and how to spare?]

Authors:  Bernhard Hellmich
Journal:  Z Rheumatol       Date:  2021-03-12       Impact factor: 1.372

Review 2.  An Updated Review of Cardiovascular Events in Giant Cell Arteritis.

Authors:  Hubert de Boysson; Achille Aouba
Journal:  J Clin Med       Date:  2022-02-15       Impact factor: 4.241

Review 3.  Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica.

Authors:  Dario Camellino; Eric L Matteson; Frank Buttgereit; Christian Dejaco
Journal:  Nat Rev Rheumatol       Date:  2020-08-05       Impact factor: 20.543

4.  Symptomatic aortitis at giant cell arteritis diagnosis: a prognostic factor of aortic event.

Authors:  Olivier Espitia; Gauthier Blonz; Geoffrey Urbanski; Cédric Landron; Jérôme Connault; Christian Lavigne; Pascal Roblot; François Maillot; Alexandra Audemard-Verger; Mathieu Artifoni; Cécile Durant; Béatrice Guyomarch; Mohamed Hamidou; Julie Magnant; Christian Agard
Journal:  Arthritis Res Ther       Date:  2021-01-07       Impact factor: 5.156

5.  Analysis of Development Mechanism of Giant Cell Arteritis in Nude Mouse Model through Color Duplex Sonography and Computerized Tomography Nanocontrast Agent.

Authors:  Fugang Chen; Yang Li; Hongyan Zhou; Chuang Sun; Sun Li; Lu Wang; Xin Li; Xiaoqiang Liu
Journal:  Biomed Res Int       Date:  2021-04-09       Impact factor: 3.411

Review 6.  Mimickers of Large Vessel Giant Cell Arteritis.

Authors:  André Ramon; Hélène Greigert; Paul Ornetti; Bernard Bonnotte; Maxime Samson
Journal:  J Clin Med       Date:  2022-01-19       Impact factor: 4.241

7.  Impact of Glucocorticoid Cumulative Doses in a Real-Life Cohort of Patients Affected by Giant Cell Arteritis.

Authors:  Paul Castan; Anael Dumont; Samuel Deshayes; Jonathan Boutemy; Nicolas Martin Silva; Gwénola Maigné; Alexandre Nguyen; Sophie Gallou; Audrey Sultan; Achille Aouba; Hubert de Boysson
Journal:  J Clin Med       Date:  2022-02-16       Impact factor: 4.241

8.  European Headache Federation recommendations for neurologists managing giant cell arteritis.

Authors:  S P Mollan; K Paemeleire; J Versijpt; R Luqmani; A J Sinclair
Journal:  J Headache Pain       Date:  2020-03-17       Impact factor: 7.277

Review 9.  Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future.

Authors:  B Hellmich; A F Águeda; S Monti; R Luqmani
Journal:  Curr Rheumatol Rep       Date:  2020-10-12       Impact factor: 4.592

10.  Large-vessel involvement is predictive of multiple relapses in giant cell arteritis.

Authors:  Donatienne de Mornac; Olivier Espitia; Antoine Néel; Jérôme Connault; Agathe Masseau; Alexandra Espitia-Thibault; Mathieu Artifoni; Aurélie Achille; Anaïs Wahbi; Mathieu Lacou; Cécile Durant; Pierre Pottier; François Perrin; Julie Graveleau; Mohamed Hamidou; Jean-Benoit Hardouin; Christian Agard
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-05-18       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.